149 Commonwealth Drive
350 articles with Geron Corporation
Geron Corporation reported financial results for the third quarter and year-to-date as of September 30, 2019 as well as recent events.
Geron Corporation (Nasdaq: GERN) today announced that it will release its third quarter 2019 financial results after the market closes on Wednesday, November 6, 2019 via press release, which will be available on the Company’s website at www.geron.com/investors
Geron Corporation reported that it has granted non-statutory stock options to purchase an aggregate of 200,000 shares of Geron common stock as inducements to three newly-hired employees in connection with commencement of employment with the Company.
10/14/2019It was a busy week for clinical trial announcements. Here’s a look.
Geron Announces First Patient Dosed in IMerge Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes
Geron Corporation (Nasdaq: GERN) today announced that the first patient has been dosed in the IMerge Phase 3 clinical trial to evaluate imetelstat, a first-in-class telomerase inhibitor, in lower risk myelodysplastic syndromes (MDS).
1/4/2019Biopharma companies begin 2019 with a flurry of hiring to fill executive leadership spots, including Dermavant, UroGen, Melinta, Translate Bio, and more.
Geron Corporation, located in Menlo Park, Calif., announced that Janssen Biotech, a Johnson & Johnson company, had terminated their 2014 Collaboration and License Agreement.
As we move into the last quarter of 2018, plenty of companies are looking at potential catalysts. George Budwell, writing for The Motley Fool, takes a look at three potentially high-reward biotech companies, but along with their big catalysts comes high risk.
Although the overall stock market has been a bit jittery as the result of a trade war, biotech stocks have been surprisingly steady—at least in comparison to their usual volatility.
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Geron Corporation (GERN)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Geron Corporation ("Geron" or the "Company") (NASDAQ: GERN)
The presentations are available on Geron’s website at www.geron.com/presentations.
These companies are important to follow as they have exponential growth potential and are working on new and innovative drugs.
Management to be joined by external guest speaker to review imetelstat data from IMerge to be presented at the 59th American Society of Hematology Annual Meeting and Exposition.
Geron Announces First Patient Dosed in Expanded Part 1 of IMerge Clinical Trial in Myelodysplastic Syndromes
Imetelstat is a telomerase inhibitor initially developed by Geron and exclusively licensed to Janssen Biotech, Inc. (Janssen) on a worldwide basis.
Geron Announces Fast Track Designation Granted to Imetelstat for Lower Risk Myelodysplastic Syndromes
Janssen sponsored the application for Fast Track designation utilizing preliminary data from IMerge, the ongoing clinical trial being conducted by Janssen in lower risk MDS.
Geron’s management will also host a conference call to discuss the company’s third quarter results and recent events.